PRME Prime Medicine, Inc.

NASDAQ
$3.09

Prime Medicine, Inc. (PRME) is expected to report earnings on November 5, 2026, after the market close. The consensus earnings estimate is a loss of $0.23 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +1.0% since its last earnings release on August 6, 2026.

Prime Medicine Reported In-line with Estimates
Thursday, August 6, 2026 · 8:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 5
Thursday · After Close
Earnings Whisper
-
vs ($0.23)
Rev est $5.43M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $3.12

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Prime Medicine, Inc.

Prime Medicine Inc. is a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies. Prime Medicine Inc. is based in CAMBRIDGE, Mass.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow